NCT03118778 (ECHO) is a clinical trial in Gastrointestinal Disease, sponsored by AstraZeneca.

Who is sponsoring NCT03118778?

NCT03118778 is sponsored by AstraZeneca.

What condition does NCT03118778 study?

NCT03118778 studies Gastrointestinal Disease.

Is NCT03118778 still recruiting?

NCT03118778 is currently completed. Last updated 12 July 2018.

Last reviewed 2018-07-12 · How we verify

NCT03118778: ECHO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population

Completed Last updated 12 July 2018

What this trial tests

trial in Gastrointestinal Disease in 90,895 participants. Completed in 10 July 2017.

Timeline

28 April 2017

Primary endpoint
10 July 2017

10 July 2017

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	90,895
Start date	28 April 2017
Primary completion	10 July 2017
Estimated completion	10 July 2017
Sites	1 location across China

Conditions studied

Gastrointestinal Disease — all drugs for Gastrointestinal Disease →

Sponsor

AstraZeneca — full company profile →

Who can join

Eligibility, any sex, with Gastrointestinal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a descriptive retrospective database analysis study in using database. All patients with a physician PPI prescription will be selected to estimate the PPI inappropriate use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gastrointestinal Disease

Currently open trials in the same condition.

NCT05053191 — Advancing Nursing Practices in Hospital Oncology Care · NA · active not recruiting
NCT04949282 — Spanish Series of Patients Treated With the Radionuclide Lutetium177 · recruiting
NCT03566160 — Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy · NA · active not recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03118778 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 12 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03118778.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing